Thermo Fisher Scientific Nivolumab Recombinant Rabbit Monoclonal Antibody (40F11), Biotin, MonoRab

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Blocking Assay (BLOCK)

10-50 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Expression System

Mammalian cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

40F11

Immunogen

Nivolumab

Conjugate

Biotin Biotin Biotin

View additional formats

• Unconjugated
• Request custom conjugation

Form

Lyophilized

Purification

Protein A

Storage buffer

PBS, pH 7.4, with 1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Nivolumab is a fully human monoclonal IgG4 antibody that is approved by the U.S. Food and Drug Administration for the treatment of bladder cancer. It binds to the programmed cell death protein 1 (PD-1) on the surface of activated T cells. Nivolumab functions as PD-1 inhibitor for targeted immunotherapy.GenScript MonoRab™ Anti-Nivolumab Antibody (40F11), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Nivolumab.

Target Information

Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.